A PHASE I/II, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF THE ANTIBODY-DRUG CONJUGATE GSK2857916 ADMINISTERED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE (ARM A), OR BORTEZOMIB PLUS DEXAMETHASONE (ARM B) IN PARTICIPANTS WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA-DREAMM 6
2017-004689-93MIELOMA MÚLTIPLE RECIDIVANTE O RESISTENTEFundación Jiménez DíazInvestigador: ASKARI ASKARI ELHAM
